NNM Securities

JAGSONPAL PHARMACEUTICALS LTD.

NSE : JAGSNPHARMBSE : 507789ISIN CODE : INE048B01027Industry : Pharmaceuticals & DrugsHouse : Jagsonpal

BSE361.253.85 (+1.08 %)

PREV CLOSE ( ) 357.40

OPEN PRICE ( ) 357.40

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 575

TODAY'S LOW / HIGH ( )351.35 368.25

52 WK LOW / HIGH ( )270.05 513.9

NSE361.053.35 (+0.94 %)

PREV CLOSE( ) 357.70

OPEN PRICE ( ) 361.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 361.05 (44)

VOLUME 16385

TODAY'S LOW / HIGH( ) 352.00 375.50

52 WK LOW / HIGH ( )273.6 514.85

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 17-08 1978

Management Info

Harsha Raghavan - Chairman Manish Gupta - Managing Director

Registered Office

Address T 210 J,Shabpur Jat, ,
New Delhi,
Delhi-110049

Phone 011-46181100 / 46109900

Email cs@jagsonpal.com

Website www.jagsonpal.com

Registrars Details

MCS Ltd

F-65, ,Okhla Industrial Area,Phase - I,New Delhi

Listing : BSE, NSE, MCX

NEWS

01Apr Announcement under Regulation 30 (LOD
Pursuant to SEBI ( Listing Obligations and Disclosure Requirements), 201..

09Mar Jagsonpal Pharmaceuticals launches ‘Qu
Jagsonpal Pharmaceuticals has launched QueeZy-ER providing relief from N..

08Mar Jagsonpal Pharmaceutical launches Quee
Jagsonpal Pharmaceutical has launched QueeZy-ER providing relief from Na..

08Mar Jagsonpal Pharmaceuticals informs abou
In terms of regulation 30 of the SEBI (LODR) Regulations, 2015, Jagsonpa..

29Sep Jagsonpal Pharmaceuticals informs abou
Jagsonpal Pharmaceuticals has informed that the Trading Window for deali..

Financials

Rs. in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	39.63	267.21
Gross Profit	52.79	348.08
Operating Profit	59.17	398.85
Net Sales	472.34	2367.14

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 26643.70 (0.58%)	M.Cap (Rs. in Cr)56616.00
Pfizer (BSE) 4473.85 (1.59%)	M.Cap (Rs. in Cr)20466.85
Glaxosmithkline Phar (BSE) 2355.75 (2.80%)	M.Cap (Rs. in Cr)39907.83
Concord Biotech (BSE) 1494.85 (4.43%)	M.Cap (Rs. in Cr)15638.55
Zydus Lifesciences (BSE) 1104.45 (5.00%)	M.Cap (Rs. in Cr)111133.51

Shareholding Pattern

	PROMOTERS	68.09%
	NON-INSTITUTION	30.33%
	FI/BANKS/INSURANCE	0%
	MUTUAL FUNDS/UTI	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Motilal Oswal S&P B...	0.02

ATTENTION INVESTORSKYCIPO

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :

Assamese	Bengali	Gujrati	Hindi	Kanada
Kashmiri	Konkani	Malyalam	Marathi	Oriya
Punjabi	Sindhi	Tamil	Telegu	Urdu

REGISTRATION NOS.

Filing compliant on SCORES – Easy & quick

Register on SCORES portal
Mandatory details for filing complaints on SCORES:
- Name
- PAN
- Address
- Mobile Number
- E-mail ID
Benefits:
- i.) Effective communication
- ii.) Speedy redressal of the grievances

SMART ODR Portal

Notices/Communique Links

BSE | NSE | MCX | CDSL

INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

NNM Securities

Smart Quotes

JAGSONPAL PHARMACEUTICALS LTD.

Filing compliant on SCORES – Easy & quick

Notices/Communique Links